These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2227540)

  • 1. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.
    Stringer CA; Gershenson DM; Burke TW; Edwards CL; Gordon AN; Wharton JT
    Gynecol Oncol; 1990 Sep; 38(3):305-8. PubMed ID: 2227540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
    Burke TW; Gershenson DM; Morris M; Stringer CA; Levenback C; Tortolero-Luna G; Baker VV
    Gynecol Oncol; 1994 Oct; 55(1):47-50. PubMed ID: 7959265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
    Smith MR; Peters WA; Drescher CW
    Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
    Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
    Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
    Chambers JT; Chambers SK; Kohorn EI; Carcangiu ML; Schwartz PE
    Gynecol Oncol; 1996 Mar; 60(3):438-42. PubMed ID: 8774654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Burke TW; Stringer CA; Morris M; Freedman RS; Gershenson DM; Kavanagh JJ; Edwards CL
    Gynecol Oncol; 1991 Mar; 40(3):264-7. PubMed ID: 2013451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
    J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
    Hempling RE; Piver MS; Baker TR
    Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
    Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
    Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide.
    Dunton CJ; Pfeifer SM; Braitman LE; Morgan MA; Carlson JA; Mikuta JJ
    Gynecol Oncol; 1991 May; 41(2):113-6. PubMed ID: 2050302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant chemotherapy with cyclophosphamide, adriamycin, and CDDP (CAP) for high risk endometrial cancer after complete surgery].
    Tsunoda H; Nishida M; Arisawa Y; Sato T; Oki A; Nishide K; Ichikawa Y; Kubo T
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Jan; 48(1):45-51. PubMed ID: 8576621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
    Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC).
    Price FV; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT
    Gynecol Oncol; 1993 Dec; 51(3):383-9. PubMed ID: 8112650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.